# nature biotechnology

Article

# Whole-body cellular mapping in mouse using standard IgG antibodies

Received: 12 August 2022

Accepted: 26 May 2023

Published online: 10 July 2023

Check for updates

Hongcheng Mai<sup>1,2,3,4,14</sup>, Jie Luo<sup>1,2,4,14</sup>, Luciano Hoeher<sup>1</sup>, Rami Al-Maskari<sup>1,5</sup>, Izabela Horvath <sup>®</sup> <sup>1,5</sup>, Ying Chen<sup>1,2,6</sup>, Florian Kofler<sup>7,8,9,10</sup>, Marie Piraud<sup>7</sup>, Johannes C. Paetzold<sup>1,11</sup>, Jennifer Modamio<sup>1</sup>, Mihail Todorov<sup>1,2,12</sup>, Markus Elsner <sup>®</sup><sup>1</sup>, Farida Hellal<sup>1,2,12</sup> & Ali Ertürk <sup>®</sup> <sup>1,2,4,12,13</sup>

Whole-body imaging techniques play a vital role in exploring the interplay of physiological systems in maintaining health and driving disease. We introduce wildDISCO, a new approach for whole-body immunolabeling, optical clearing and imaging in mice, circumventing the need for transgenic reporter animals or nanobody labeling and so overcoming existing technical limitations. We identified heptakis(2,6-di-O-methyl)-β-cyclodextrin as a potent enhancer of cholesterol extraction and membrane permeabilization, enabling deep, homogeneous penetration of standard antibodies without aggregation. WildDISCO facilitates imaging of peripheral nervous systems, lymphatic vessels and immune cells in whole mice at cellular resolution by labeling diverse endogenous proteins. Additionally, we examined rare proliferating cells and the effects of biological perturbations, as demonstrated in germ-free mice. We applied wildDISCO to map tertiary lymphoid structures in the context of breast cancer, considering both primary tumor and metastases throughout the mouse body. An atlas of high-resolution images showcasing mouse nervous, lymphatic and vascular systems is accessible at http://discotechnologies.org/wildDISCO/atlas/index.php.

More than a century of dedicated work has provided a detailed understanding of the gross anatomy of the human body and the body of common model organisms and has produced detailed histological maps of many individual organs. However, it remains challenging to map the distribution, connectivity and molecular makeup of cell types across the whole body for a given experimental condition. For instance, although the nervous system pervades every region of the mammalian body, cellular-level maps depicting the intricate web of nerves linking various organs and connecting them to the central nervous system are still lacking<sup>1-3</sup>. In addition, most methods to image nerves or other cells in the context of whole bodies rely on transgenic animals<sup>4,5</sup>, which limits the flexibility of experimental design. Generating transgenic animals to map changes in the distribution of relevant proteins is usually prohibitively expensive and time consuming. However, such whole-body connectivity maps will be needed to understand the functional interdependence of organ systems and how a disease starting

<sup>1</sup>Institute for Tissue Engineering and Regenerative Medicine, Helmholtz Center Munich, Neuherberg, Germany. <sup>2</sup>Institute for Stroke and Dementia Research, Medical Centre of the University of Munich, Ludwig-Maximilians University of Munich, Munich, Germany. <sup>3</sup>Munich Medical Research School, Munich, Germany. <sup>4</sup>Deep Piction GmbH, Munich, Germany. <sup>5</sup>TUM School of Computation, Information and Technology, Technical University of Munich, Munich, Germany. <sup>6</sup>Faculty of Medicine, Ludwig-Maximilians University of Munich, Munich, Germany. <sup>7</sup>Helmholtz Al, Helmholtz Center Munich, Neuherberg, Germany. <sup>8</sup>Department of Informatics, Technical University of Munich, Munich, Germany. <sup>9</sup>TranslaTUM – Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany. <sup>10</sup>Department of Diagnostic and Interventional Neuroradiology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. <sup>11</sup>Department of Computing, Imperial College London, London, UK. <sup>12</sup>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. <sup>13</sup>Graduate School of Neuroscience (GSN), Munich, Germany. <sup>14</sup>These authors contributed equally: Hongcheng Mai, Jie Luo. e-mail: ali.erturk@helmholtz-munich.de in one part of the body affects distal organs and tissues, for example, during neurodegeneration or systemic inflammation.

Recent clearing methods have enabled labeling and imaging of intact tissues<sup>6</sup>, mouse organs<sup>7</sup> and bodies<sup>3,8-15</sup>, parts of human organs<sup>16</sup> and even human embryos<sup>17</sup>. While previous methods, such as CUBIC, PACT, PEGASOS and uDISCO, enabled whole-body imaging, they relied on transgenic expression of fluorescent proteins in a subset of cells, such as mice expressing Thy-1 enhanced green fluorescent protein (EGFP) in neurons<sup>18</sup>. For example, vDISCO<sup>5</sup> relies on the small antibody fragments called nanobodies (roughly one-tenth of IgG size) for whole mouse body labeling. Despite the thousands of conventional antibodies that have been developed over the past decades, only a handful of nanobodies are available or function effectively in a histological context. Consequently, we still lack appropriate, universally applicable labeling methods for whole mouse bodies that use standard IgG antibodies.

Although homogeneous labeling of whole bodies with small molecules (for example, DNA-labeling dyes) or nanobodies can be achieved by cardiac pumping of solutions through the mouse vasculature<sup>5</sup>, standard IgG antibodies face several challenges. These include degradation or precipitation during perfusion, inability to consistently penetrate various tissue layers—including muscles and bones—and insufficient membrane permeabilization to reach deep into all tissues with diverse properties.

To overcome these challenges, we developed wildDISCO (immunolabeling of wildtype mice and DISCO clearing), a chemical method enhancing the penetration of standard (roughly 150 kDa in size) antibodies into the whole roughly 2 cm-thick mouse body. Our method relies on cholesterol extraction for permeabilization to ensure homogeneous penetration and staining across the tissues of the whole mouse body including muscles, bones, the brain and the spinal cord. Combining whole-body antibody labeling with DISCO-based tissue clearing allowed us to provide body-wide maps of cell-type and protein distribution with unprecedented ease and will help advance our understanding of biological systems.

#### Results

#### Development of wildDISCO

We hypothesized that poor cholesterol extraction from cell membranes might have been a factor limiting tissue permeabilization in previous methods. Cyclodextrin is a small oligosaccharide ring used to deplete cholesterol in live membranes<sup>12</sup>. We screened for  $\beta$ -cyclodextrin variants with a diverse nature and number of R-motifs (for example, methyl-, hydroxypropyl-, hydroxyethyl-, succinyl- and acetyl-) (Fig. 1a) for their potential ability to facilitate cholesterol extraction in fixed samples in combination with the CHAPS and Triton X-100 detergents to enhance permeabilization. Assessing cholesterol extraction using the cholesterol and cholesterol ester-glo assay, we found that the hept akis(2,6-di-O-methyl)-B-cyclodextrin (CD5) extracted most cholesterol from mouse liver tissue after 7 days (Fig. 1b). Addition of CD5 to the permeabilization reactions allowed rapid and homogeneous penetration of methylene blue into the whole mouse brain within 12 h, whereas other tested cyclodextrin chemicals allowed only limited penetration (Fig. 1c and Supplementary Fig. 1).

Fig. 1 | Exploring cyclodextrins as whole-body conventional IgG antibody staining chemicals and comparison of different clearing methods for whole mouse antibody staining. a, The structure of cyclodextrin (CD) with different substituent groups: CD1 (methyl- $\beta$ -cyclodextrin), CD2 (2-hydroxypropyl- $\beta$ -cyclodextrin), CD3 (triacetyl- $\beta$ -cyclodextrin), CD4 ((2-hydroxyethyl)- $\beta$ cyclodextrin), CD5 (heptakis(2,6-di-O-methyl)- $\beta$ -cyclodextrin) and CD6 (succinyl- $\beta$ -cyclodextrin). b, Measurements of supernatant cholesterol concentration after different CD-containing buffer incubation on the seventh day for 25 mg mouse liver sections. c, Methylene blue staining of a single hemisphere of mouse brains after permeabilization with different CD-containing solutions. As cyclodextrins have been previously reported to stabilize proteins in solution by preventing aggregation<sup>19</sup>, we also measured the antibody size in antibody solutions using dynamic light scattering (DLS). We found that after 7 days at room temperature in a HEPES buffer without CD5, antibodies showed two peaks in the DLS data: one peak at 11.5 nm presumably for the antibody monomer and a peak for larger sizes, which most likely corresponds to different aggregation states. Thus, addition of CD5 prevented the formation of aggregates (Fig. 1d).

We next tested whether the enhanced membrane permeabilization and the decreased aggregation<sup>20</sup> propensity of antibodies in the CD5-containing buffers translated into an increased homogeneity and depth of antibody staining in whole mouse bodies. We were able to demonstrate whole mouse labeling using active perfusion of the CD5-containing staining solution and called this protocol wildDISCO (Supplementary Fig. 2). We compared different cyclodextrins for kidney staining and found that CD5 supported the most uniform antibody penetration (Supplementary Fig. 3). Furthermore, we tested the penetration of an antibody against tyrosine hydroxylase (TH)<sup>+</sup>, a marker of sympathetic nerves, into the whole mouse body with and without CD5 using passive staining and found that antibodies quickly aggregated without CD5 (Supplementary Fig. 4). In contrast to active perfusion, passive staining yielded only partial antibody penetration. Using passive diffusion, we found few TH<sup>+</sup> sympathetic nerves in the forelimb and no sympathetic nerve staining in the liver, indicating that antibody penetration requires perfusion through the mouse vasculature to achieve a homogeneous staining throughout the body. To determine the optimal perfusion time, we stained mice with a synapsin 1 antibody (Supplementary Fig. 5) for 1 and 7 days. While peripheral tissues such as the hindlimbs were already well stained after 1 day (Supplementary Fig. 5b,c,g,h), uniform staining of synapsin 1 in internal organs, such as the liver (Supplementary Fig. 5d,e,i,j), required a 7-day perfusion. Therefore, a 7-day active perfusion-based wildDISCO yielded the best results for most applications ensuring a complete antibody penetration and binding to the target antigens.

We evaluated wildDISCO against other established methods (vDISCO, iDISCO, uDISCO and PEGASOS) in terms of their efficacy in staining an entire mouse using standard antibodies. In a direct side-by-side comparison using the synapsin 1 antibody, we observed incomplete staining in addition to many blurry imaged organs (such as the head and hindlimbs) from iDISCO, uDISCO and PEGASOS stained samples (probably due to the lack of a decalcification step in these protocols) (Fig. 1e–g). Although vDISCO is able to stain whole mouse bodies with nanobodies, it has already been reported not to provide deep tissue staining with standard IgG antibodies<sup>5</sup>, as we confirmed in our new set of experiments. By contrast, wildDISCO enabled full penetration of antibodies homogeneously and deeply into whole mouse internal organs, such as hindlimbs, spinal cord, forelimbs, kidneys and liver (Fig. 1f–i and Supplementary Fig. 6).

To test its reproducibility, we applied wildDISCO at the same time on five different mice and labeled them with TH antibodies. Quantifying the sympathetic nerve intensity, we demonstrated that there was no statistical difference in the labeling between different mice, validating the high reproducibility of our wildDISCO methodology (Supplementary Fig. 7).

CD5 is shown to greatly enhance tissue permeabilization compared to others. **d**, DLS for size distribution of TH antibody in solutions with and without CD5. **e**-**i**, Comparison of different clearing methods for whole mouse body antibody staining. **e**, Optical 2D light-sheet microscopy images of the whole mouse body stained with synapsin 1 antibody by wildDISCO, vDISCO, iDISCO, uDISCO and PEGASOS methods, respectively. Scale bar, 5,000  $\mu$ m. **f**,**g**, Representative 2D optical images of mouse hindlimb (**f**) and spinal cord (**g**) by wildDISCO, vDISCO, iDISCO, uDISCO, iDISCO, uDISCO, uDISCO, iDISCO, uDISCO, iDISCO, uDISCO, iDISCO, uDISCO, uDISCO, uDISCO, vDISCO, iDISCO, uDISCO, uDISCO, vDISCO, iDISCO, uDISCO, uD At present, reporter mice are predominantly used for imaging biological systems in entire mouse bodies, such as with whole-body clearing methods such as vDISCO. To investigate the accuracy of transgenic reporters in reflecting the biodistributions of the endogenous protein, we conducted a comparison with wildDISCO labeling. By labeling LYVE-1 EGFP reporter mice with LYVE-1 antibody using wildDISCO, we



were able to show that the LYVE-1 transgenic reporter (which expresses EGFP under the LYVE-1 promoter from a construct integrated at a different genomic locus) only partially labels structures expressing the endogenous proteins (Supplementary Fig. 8). This suggests that transgenic reporters may not accurately represent the full distribution of endogenous proteins, underscoring the power of wildDISCO to ensure a more faithful portrayal of protein distribution in biological systems.

#### wildDISCO labels body-wide systems

The sympathetic and parasympathetic systems are major parts of the autonomic nervous system that regulates and coordinates organ function. To provide a complete map of the innervation of organs in mice, we stained the peripheral neuronal network in young adult mouse bodies (roughly 4 weeks old, roughly  $10 \times 3 \times 2$  cm dimensions) using protein gene product 9.5 (PGP 9.5), a pan-neuronal marker, and imaged it at cellular resolution in its entirety using light-sheet microscopy (Fig. 2a, Extended Data Fig. 1 and Supplementary Video 1). The peripheral nerve system was homogeneously stained throughout the entire depth of the mouse body without apparent differences in signal intensity between tissues as different as vertebrae (Fig. 2b) and adipose tissue (Fig. 2c).

In the heart, for example, the network of nerve fibers coursing through the ventricular myocardium was evident (Extended Data Fig. 1b and Supplementary Video 2). The splenic parenchyma showed the nerve fibers' complex, panicle-like architecture. The vagus nerve branched into smaller fiber bundles as it progressed toward the dorsal spleen, where we also visualized the splenic neural network (Extended Data Fig. 1c and Supplementary Video 3). Nerve fibers also innervated the hepatic sinusoids and distributed along the hepatic duct end-to-end. In the gallbladder, the ganglionated plexus comprising a series of irregularly shaped ganglia was clearly visible (Extended Data Fig. 1d and Supplementary Video 4). Whole mouse body tracing of nerves enabled us to visualize nerve connections between different organs (Fig. 2d,e and Supplementary Video 5), which will provide essential clues for understanding the role of nerve communication in normal physiology and disease.

Next, we assessed the sympathetic innervation of diverse organs using the sympathetic nerve marker TH. TH<sup>+</sup> nerves were found throughout the body (Extended Data Fig. 2a), in most organs including the brain (Extended Data Fig. 2b,c) and visceral organs in 4-week-old mice. In the small intestine, the interconnected ganglionated plexuses on the intestinal wall were observed (Supplementary Video 6). We traced the vagus nerve (Fig. 2f,g and Supplementary Video 7) and showed that it provides sympathetic innervation to the abdominal organs and that it connects visceral organs, such as the kidneys, adrenal gland, ureter, liver, spleen and gastrointestinal tract. We obtained similar results in 3-month-old mice (Supplementary Fig. 9).

To show the generalizability of the approach, we also mapped the lymphatic system across the mouse body using the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1). We observed the finely structured lymphatic network throughout the body (Fig. 2h, Extended Data Fig. 3 and Supplementary Video 8) and could visualize details of lymph vessel organization in individual organs. For example, LYVE-1<sup>+</sup> vessels were observed in the hepatic sinusoidal endothelium and the superficial gastrocnemius (Extended Data Fig. 3a,b). LYVE-1<sup>+</sup> lymph nodes could be observed near the hindlimbs (Supplementary Video 9). Especially in adipose tissue, we observed a large variety in the shape and size of LYVE-1<sup>+</sup> cells (Extended Data Fig. 3c). The larger lymphatic vessels of the kidney branched into lymphatic capillaries with a tree-like architecture (Extended Data Fig. 3d and Supplementary Video 10). Tracheal lymphatic vessels showed a segmental pattern of interconnected vessels (Extended Data Fig. 3e). In the stomach, lymphatics were unevenly distributed on the gastric walls and had tree-like branches (Extended Data Fig. 3f,i and Supplementary Video 11). Blunt-ended, tube-like lymphatic capillaries (lacteals)<sup>21</sup> were clearly located in the intestinal villi (Supplementary Video 12), and the abundant and well-organized

lymphatic plexuses and networks were visible on the outer surface of the intestinal wall (Extended Data Fig. 3g,h and Supplementary Video 13).

The brain parenchyma has been thought to be devoid of lymphatic vessels<sup>22,23</sup>, although there is lymphatic drainage from the central nervous system via meningeal lymphatic vessels<sup>24</sup>. Our whole-body immunolabeling data showed small and short lymphatic capillaries entering the brain parenchyma from the meninges. Some LYVE-1<sup>+</sup> lymphatic vessels are also observed to connect the olfactory bulb with the cortex (Fig. 2i and Supplementary Video 14). These connections were observed by both LYVE1 and Prox1 (Prospero homeobox protein 1, a marker for lymphatic endothelium) staining. We also find lymph vessels entering the brain parenchyma around the thalamus (Supplementary Video 15), which was confirmed by both LYVE1 and podoplanin staining (Fig. 2j). Furthermore, we traced the LYVE1 lymphatic vessels from the brain to the vertebrae (Supplementary Video 16). We also extended LYVE1 labeling to mice with the skin. We could clearly visualize the network of lymphatic vessels in the skin. However, scanning of lymphatic vessels deep within internal organs while the skin was intact yielded poor-quality images. Imaging quality was restored when the skin was removed, and the mice were rescanned (Supplementary Fig. 10 and Supplementary Video 17).

Next, we used wildDISCO to generate a body-wide map of arteries. We used alpha-SMA as an arterial marker (Extended Data Fig. 4), and observed continuous arteries in multiple organs, including the brain, liver, spleen, heart and spinal cord. Particularly in the head, in the heart and near the spinal cord (Extended Data Fig. 5), we clearly observed the blood vessel connections and proved the integrity of vasculature staining.

#### wildDISCO is compatible with double labeling

Next, we investigated whether wildDISCO can be used to label more than one protein in the same sample, as this would allow us to study the relationship of different physiological systems using conventional antibodies.

First, we coimmunolabeled TH<sup>+</sup> sympathetic nerves and CD45<sup>+</sup> immune cells (Fig. 3a–d, Extended Data Fig. 6 and Supplementary Video 18). We find substantial colocalization of immune cells along parts of the sympathetic nervous system, especially at the inferior mesenteric plexus (Fig. 3b), and frequent contacts between immune cells and sympathetic nerves on the intestinal wall (Fig. 3c,d). To better illustrate neuro-immune interactions in the lymphatic system, especially the lymph nodes, we used double staining of nerve fibers and lymphatic vessels (Fig. 3e, Extended Data Fig. 7, Supplementary Fig. 11 and Supplementary Videos 19–22). LYVE1<sup>+</sup> and Prox1<sup>+</sup> lymph nodes were often innervated with TH<sup>+</sup> (sympathetic neuronal marker) or PGP 9.5<sup>+</sup> (pan-neuronal marker) neuronal processes (Fig. 3f,g and Supplementary Videos 23 and 24). Double staining of nerve and lymphatic cells, as well as nerve and immune cells, revealed the intricate interactions of these systems throughout the body.

#### wildDISCO reveals neuronal abnormalities in germ-free mice

Next, we used wildDISCO to study perturbations of biological systems at whole mouse body level. Microbiota, which are the collection of microorganisms that live in and on the body, have been suggested to play an important role in the development and function of the nervous system<sup>25</sup>. For example, germ-free mice have been shown to have altered behavior, including increased anxiety-like behavior and impaired social behavior<sup>26,27</sup>. Although these behavioral changes may be related to alterations in neural development and function that occur in the absence of microbiota, the extent of the structural abnormalities across the whole body remains to be explored. Comparing the structure of the nervous system of germ-free mice and wildtype controls, we found that the PGP 9.5+ nerve lattice network in the intestinal wall was substantially less dense in 4-week-old germ-free mice compared



**Fig. 2** | **Comprehensive neuroanatomical and lymphatic mapping of the whole mouse body using wildDISCO. a**, Depth color coding shows the panneuronal marker PGP 9.5<sup>+</sup> neuronal projections at different *z* levels in the 2.0 cm-thick whole mouse body. Scale bar, 2,000 μm. **b**,**c**, Details of innervation throughout hard (vertebrae) (**b**) and soft tissues (adipose tissue) (**c**). Scale bars, 200 μm. **d**, Optical 2D section showed the PGP 9.5<sup>+</sup> nerve innervation into multiple organs. Scale bar, 1,200 μm. **e**, Segmented vagus nerves innervating the kidney (magenta), adrenal gland (green), ureter (cyan), highlighted with specific pseudo-colors. Scale bar, 800 μm. **f**, Tracing of the TH<sup>+</sup> vagus nerve over several

organs. A single traced vagus nerve masked in magenta from the bottom of the spinal cord to the neck, kidney masked in green and liver masked in cyan. Scale bar, 4,000  $\mu$ m. **g**, Higher magnification of the trajectories of the vagus nerve in the mouse can be determined. Scale bar, 1,500  $\mu$ m. **h**, A whole mouse stained with a lymphatic vessel marker LYVE1 (yellow). Scale bar, 2,000  $\mu$ m. **i**, Lymphoid elements (LYVE1) staining was detected in the brain parenchyma of the mouse. Scale bar, 150  $\mu$ m. **j**, Mouse brains stained with two different lymphatic vessel markers (LYVE1 and podoplanin) to identify lymphatic endothelial cells found in the brain regions. Scale bar, 100  $\mu$ m. **b**–**j**, n = 3.



to same aged wildtype controls (Fig. 3h and Extended Data Fig. 8). In 3-month-old germ-free mice, axons were even more degenerated and the lattice network less dense than in 4-week-old germ-free mice (Fig. 3i-1). These findings suggest that the microbiome plays a role in axon development and innervation of peripheral body regions<sup>28</sup> throughout different ages of the mice.

Revealing tertiary lymphoid structures and rare cells

Next, we investigated rare structures called tertiary lymphoid structures (TLS) in tumor-bearing mice. TLS are organized aggregates of immune cells that form in non-lymphoid tissues. TLS are not found under physiological conditions but arise in the context of autoimmune disease and cancer. For example, TLS can promote infiltration Fig. 3 | Different physiological system staining using wildDISCO. a, Maximum intensity projection of a mouse stained with antibodies against the TH (green) and the immune cell marker CD45 (magenta), showing the landscape of neuro-immune interactions in internal organs. Scale bar, 1,000  $\mu$ m. b, The branches of the sympathetic nervous system (TH, green) connect different regions of the intestine. CD45<sup>+</sup> cells (magenta) accumulate along parts of the sympathetic nerve, especially at the inferior mesenteric plexus. Scale bar, 200  $\mu$ m. c, Highmagnification views of the labeled regions in a, showing the colocalization of the sympathetic nerve fibers and immune cells on the intestinal wall. Scale bar, 200  $\mu$ m. d, Representative 2D optical sections of peripheral nerves with immunomodulatory in lymph node (LN) stained with TH and CD45. Scale bar, 100  $\mu$ m. e, Maximum intensity projections of a whole mouse stained with TH

of immune cells into the tumor site. They also attracted interest as a means of enhancing anticancer immunity<sup>29</sup>. However, how TLS are distributed throughout the body in relation to the primary tumor and metastasis has been unclear.

To visualize TLS in the whole body with cancer metastasis, BALB/c mice were implanted with 4T1 breast cancer cells subcutaneously. After 14 days, we euthanized the mice and used wildDISCO to stain TLS using CD23 (conventional B cells and follicular dendritic cells marker) and CD3 (a T cell marker) antibodies (Fig. 4a, Extended Data Fig. 9a and Supplementary Video 25). We also demonstrated the specific signal of CD3<sup>+</sup>T cells using costaining of total immune cells with CD45 (Extended Data Fig. 9b). We find conventional B cells, follicular dendritic cells and T cells clusters and/or aggregates (denoting TLS) in the primary tumor (Fig. 4c-h) and in some metastatic sites, such as those in the lung and gut (Fig. 4b,i-l). Notably, there are no suitable reporter mice (such as CD23<sup>+</sup>) that can label TLS. This makes wildDISCO uniquely capable of investigating TLS and their distribution in whole mice.

We analyzed the size and distribution of TLS throughout the body in association with cancer metastasis. Micrometastases were randomly distributed throughout the mouse body, regardless of their volume, suggesting independent colonization at multiple sites by this tumor model. More than 80% of micrometastases were within 0.02 mm<sup>3</sup> (Fig. 4m), mainly distributed in the lung (62%) and gut (19%) (Fig. 4n). However, the spatial correlation between formation of TLS and nearby cancer metastases at the whole-body level is not clearly known. First, we quantified the volume and relative location of all TLS in the whole body. The TLS were mainly located near the lung and gut metastases. and their density was positively correlated with the metastasis density (Fig. 40). The volume of TLS was notably smaller in comparison to that of the metastases; even large TLS (average volume 0.0021 mm<sup>3</sup>) were roughly 30 times smaller than metastases (average volume 0.066 mm<sup>3</sup>) (Fig. 4p versus Fig. 4m). Given their smaller size, detecting TLS at the whole-body level using alternative methods presents a challenge. To better comprehend the spatial distribution of TLS and metastases across the entire mouse, we made several observations. First, individual TLS were often separated by a specific distance: the smallest distance between most of TLS and other TLS being average roughly 0.4 mm (Fig. 4q). Second, we noted a significant discrepancy between the distances of metastases and their closest TLS, with a majority average measurement of roughly 1,571 mm (Fig. 4r). Last, we found that the average volume of metastases to the nearest TLS is 0.023 mm<sup>3</sup>, smaller than the average metastasis size throughout the body (Fig. 4s versus (green) and LYVE1 (yellow). Scale bar, 3,000  $\mu$ m. **f**,**g**, Representative 2D optical sections of hindlimb LNs stained with TH and LYVE1 (**f**) and PGP 9.5 and Prox1 (**g**) as indicated in the images to show the LNs are innervated by peripheral nerves with immunomodulatory potential. Scale bars, 150  $\mu$ m. **h**, 3D representation of the enteric nerve lattice network of wildtype mice and germ-free mice by immunostaining with antibodies against PGP 9.5. Scale bars, 500  $\mu$ m. **i**–**l**, Highermagnification views of the regions marked by the white (**i**), red (**j**), magenta (**k**) and yellow (**l**) boxes. Scale bars, 300  $\mu$ m. **a**–**l**, *n* = 3. In the germ-free mice, the enteric nerve lattice network appears disorganized, with fewer ganglia. **m**, The density of the PGP 9.5 enteric plexus was quantified. *n* = 5; mean ± s.d.; \*\*\*\*P = 3.27 × 10<sup>-10</sup>, NS, *P* > 0.05 (one-way analysis of variance).

Fig. 4m). These insights enrich our understanding of the characteristics and interactions between TLS and metastases within the studied mouse model.

Next, we used wildDISCO to study the distribution of rare proliferating cells throughout the mouse using Ki67 antibody<sup>30</sup> labeling (Extended Data Fig. 10a). As expected, we found proliferating cells in bone marrow niches (Extended Data Fig. 10b,c), at the base of gut crypts (Extended Data Fig. 10d) and in the dentate gyrus of the hippocampus (Extended Data Fig. 10e,f). High-magnification images confirmed the specificity of the signal at the single-cell level by colocalization with the cell nucleus, as indicated by propidium iodide staining (enlarged boxes in Extended Data Fig. 10f,g). We further observed Ki67<sup>+</sup> cells in more unexpected body regions including in the spinal cord (Supplementary Videos 26 and 27). Thus, wildDISCO can provide insight into the distribution of rare cells, including proliferating cells throughout the mouse body.

#### wildDISCO generated online whole mouse atlases

After generating high-resolution images of whole mouse systems, such as the nervous system, lymphatic system and vascular system, we aimed to make these data available to the scientific community in online atlases. To this end, we established a website (Fig. 5) (http:// discotechnologies.org/wildDISCO/atlas/index.php), which allows researchers to explore our reference datasets. We provided a tutorial video (Supplementary Video 28). This website offers different views of the entire mouse (*xy*, *xz*, *yz* planes). Compared to the traditional histology sections, our whole mouse atlas provides continuous optical slices without skipping tissue regions (Fig. 5b–g). The website also offers online contrast and color adjustments (Fig. 5h–j). We envisage that this online tool will prove invaluable for biomedical research, allowing scientists to examine these systems in whole mice without the need to replicate the same experiments.

#### Discussion

We have developed a whole-body IgG antibody immunolabeling method called wildDISCO (Supplementary Video 29). The CD5-based tissue permeabilization chemistry permits uniform staining of whole bodies with conventional (150 kDa size) IgG antibodies, producing whole mouse body cellular and structural maps akin to the Allen Brain Atlas. Previously published whole mouse body clearing and imaging techniques heavily relied on transgenic reporters or small dye labeling<sup>5,31–34</sup>, which were incompatible with the thousands of commercially available IgG antibodies, limiting their applications.

**Fig. 4** | **Visualization and analysis of tumor-associated TLS in a tumor metastasis model using wildDISCO and Deep Learning. a**, 3D rendering of a mouse with 4T1 cell metastases using light-sheet microscopy imaging in ventral view. The TLS are detected and masked in magenta, the tumor cells masked in yellow and the background color is cyan. A higher magnification view shows details of the TLS. Scale bar, 2,000 μm. **b**–l, Example images of TLS in a mouse with tumors, stained with CD23 in red (**b,c**) and CD3 in green and CD23 in magenta (**d**–**g**). TLS masked in magenta in the primary tumor (**h**), gut (**i,j**) and lung (**k**,**l**). Scale bars: 500  $\mu$ m (**d**,**h**,**k**); 150  $\mu$ m (**e**,**f**,**g**,**j**); 400  $\mu$ m (**i**) and 200  $\mu$ m (**l**). **m**-**s**, Quantification of the spatial correlation between TLS and metastases throughout the mouse. **m**, Quantification of the metastasis volume across the mouse. **n**, Quantification of the metastasis density in lung and gut. *n* = 4 mice. mean ± s.d. **o**, Quantification of the distribution of TLS throughout the mouse. *n* = 4 mice. mean ± s.d. **p**, Quantification of the TLS volume across the mouse. **q**,**r**, Quantification of the distance to nearest neighboring TLS (**q**), and between metastases and the nearest TLS (**r**). **s**, The metastasis volume to the nearest TLS.

We systematically compared wildDISCO with existing clearing methods, including vDISCO<sup>5</sup>, iDISCO<sup>11</sup>, uDISCO<sup>31</sup> and PEGASOS<sup>32</sup>, demonstrating the advantages of our technology. By using wildDISCO, we

uniformly labeled and imaged various biological systems throughout entire mouse bodies, such as the nervous system, lymphatic vessels, blood vasculature, immune cells and proliferating cells.





Fig. 5 | Whole mouse body atlas website and its features. a, Flowchart outlining the process of creating a whole mouse atlas website. **b**–**f**, The representative sections of a whole-body atlas in a 3D view. Scale bar, 5,000  $\mu$ m (**b**). The images represent exemplary slices of an entire mouse taken at different depths and viewed from a dorsal perspective. For example, slices contain the spinal cord (**c**), the liver

and the lung (d), the gut and the heart (e) and the spleen (f). g, Continued optical sections and a representative image of the continued view from slices 1 to 10. h-j, Different display models. h, Opacity and color. i, j, Selection of cyan image in image color mode (i) and selection of monochrome image in layer color mode (j).

We also showed that wildDISCO can facilitate the analysis of pathogenic processes by comparing neuronal abnormalities in germ-free mice (at 4 weeks and 3 months old) and mapping TLS in cancer metastasis. As modulators of tumor immune responses, TLS are of high interest in this age of tumor immunotherapy. It has been shown that the presence and characteristics of TLS in the tumor microenvironment can influence the prognosis and response to therapy in various types of cancer. In several types of cancer, the presence of TLS has been associated with improved survival and lower rates of recurrence<sup>35</sup>. Thus, there is a growing interest in developing therapeutic strategies to modulate TLS formation and function to enhance immune responses against cancer<sup>36</sup>. However, the exact mechanisms and implications of TLS in cancer are still not completely understood. Here we presented a tool to investigate TLS at the whole mouse body level using wildDISCO. which should be of interest to the wider scientific community beyond cancer as TLS play critical roles in many diseases including autoimmune diseases such as rheumatoid arthritis and Sjögren's syndrome<sup>37</sup>, atherosclerosis<sup>38</sup> and multiple sclerosis<sup>39</sup>.

A benefit of wildDISCO is that we do not need to rely on transgenic reporters to assess proteins at the systems level. Transgenic reporter lines are in general expensive to develop and maintain, and in many cases impossible to generate. Additionally, breeding and crossing such reporter lines with the disease models is time consuming. Furthermore, such transgenic mice are limited to specific mouse strains, such as only C57BL/6 or CD-1 IGS, making it difficult to cross disease models from other backgrounds. WildDISCO overcomes these hurdles as the distribution of proteins can now be investigated in any mouse line and disease model using whole mouse IgG labeling.

Although wildDISCO has proved successful with a wide range of IgG antibodies, further validation with a broader selection of antibodies is necessary. Here, we have already listed more than 30 validated antibodies, and we will continue to update the validated antibodies regularly for the scientific community at the online website (http://discotechnologies.org/wildDISCO/). Second, the high-resolution three-dimensional (3D) imaging generated by wildDISCO results in large amounts of data that can be challenging to analyze effectively. The development of specific deep learning algorithms tailored to handle such datasets is needed for automating and streamlining the analysis process, which will enable researchers to extract valuable insights from the data more efficiently. Also, sharing terabytes of mouse at lases online is currently a challenge due to the lack of appropriate infrastructure in most research institutes. To foster collaboration and enable researchers to build on the findings of others, it is vital to develop and implement robust data sharing platforms that can handle the large-scale data generated by wildDISCO and similar imaging techniques.

In summary, wildDISCO is a whole-body IgG antibody immunolabeling method that allows researchers to obtain comprehensive cellular and structural maps of entire mouse bodies. Aided by the virtual reality (VR) visualization, previously inaccessible 3D anatomical information becomes possible (for example, see Supplementary Videos 30 and 31). By facilitating the use of off-the-shelf IgG antibodies, wildDISCO broadens the applicability of whole-body clearing and imaging techniques. Our presentation of whole mouse body atlases will enable a deeper understanding of complex biological systems. The insights gained from this technology have the potential to enhance our knowledge of disease initiation, progression and extent at the whole organism level, ultimately contributing to the development of more effective diagnostic and therapeutic strategies.

#### **Online content**

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41587-023-01846-0.

#### References

- 1. Richardson, D. S. et al. Tissue clearing. *Nat. Rev. Meth. Primers* 1, 85 (2021).
- 2. Ueda, H. R. et al. Tissue clearing and its applications in neuroscience. *Nat. Rev. Neurosci.* **21**, 61–79 (2020).
- 3. Chung, K. et al. Structural and molecular interrogation of intact biological systems. *Nature* **497**, 332–337 (2013).
- Livet, J. et al. Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. *Nature* **450**, 56–62 (2007).
- Cai, R. et al. Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull-meninges connections. *Nat. Neurosci.* 22, 317–327 (2019).
- Rios, A. C. et al. Intraclonal plasticity in mammary tumors revealed through large-scale single-cell resolution 3D imaging. *Cancer Cell* 35, 618–632.e616 (2019).
- 7. Yang, B. et al. Single-cell phenotyping within transparent intact tissue through whole-body clearing. *Cell* **158**, 945–958 (2014).
- 8. Park, Y.-G. et al. Protection of tissue physicochemical properties using polyfunctional crosslinkers. *Nat. Biotechnol.* **37**, 73–83 (2019).
- Ku, T. et al. Elasticizing tissues for reversible shape transformation and accelerated molecular labeling. *Nat. Methods* 17, 609–613 (2020).
- 10. Murray, E. et al. Simple, scalable proteomic imaging for highdimensional profiling of intact systems. *Cell* **163**, 1500–1514 (2015).
- Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. *Cell* **159**, 896–910 (2014).
- 12. Ertürk, A. et al. Three-dimensional imaging of solvent-cleared organs using 3DISCO. *Nat. Protoc.* **7**, 1983–1995 (2012).
- Susaki, E. A. et al. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. *Cell* 157, 726–739 (2014).
- Dodt, H.-U. et al. Ultramicroscopy: three-dimensional visualization of neuronal networks in the whole mouse brain. *Nat. Methods* 4, 331–336 (2007).
- Nudell, V. et al. HYBRiD: hydrogel-reinforced DISCO for clearing mammalian bodies. *Nat. Methods* 19, 479–485 (2022).
- 16. Zhao, S. et al. Cellular and molecular probing of intact human organs. *Cell* **180**, 796–812.e719 (2020).
- 17. Belle, M. et al. Tridimensional visualization and analysis of early human development. *Cell* **169**, 161–173.e112 (2017).
- Feng, G. et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. *Neuron* 28, 41–51 (2000).
- 19. Mahammad, S. & Parmryd, I. in *Methods in Membrane Lipids* (ed. Owen, D. M.) 91–102 (Springer, 2015).
- Serno, T., Geidobler, R. & Winter, G. Protein stabilization by cyclodextrins in the liquid and dried state. *Adv. Drug Delivery Rev.* 63, 1086–1106 (2011).
- Bernier-Latmani, J. & Petrova, T. V. High-resolution 3D analysis of mouse small-intestinal stroma. Nat. Protoc. 11, 1617–1629 (2016).
- 22. Cugurra, A. et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. *Science* **373**, eabf7844 (2021).
- 23. Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. *Nature* **523**, 337–341 (2015).
- 24. Jacob, L. et al. Conserved meningeal lymphatic drainage circuits in mice and humans. *J. Exp. Med.* **219**, e20220035 (2022).
- 25. Luczynski, P. et al. Growing up in a bubble: using germ-free animals to assess the influence of the gut microbiota on brain and behavior. *Int. J. Neuropsychopharmacolog.* **19**, pyw020 (2016).
- Desbonnet, L., Clarke, G., Shanahan, F., Dinan, T. G. & Cryan, J. F. Microbiota is essential for social development in the mouse. *Mol. Psychiatry* **19**, 146–148 (2014).

#### https://doi.org/10.1038/s41587-023-01846-0

- Article
- Heijtz, R. D. et al. Normal gut microbiota modulates brain development and behavior. *Proc. Natl Acad. Sci. USA* 108, 3047–3052 (2011).
- Fülling, C., Dinan, T. G. & Cryan, J. F. Gut microbe to brain signaling: what happens in vagus.... Neuron 101, 998–1002 (2019).
- Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).
- Uxa, S. et al. Ki-67 gene expression. Cell Death Differentiat. 28, 3357–3370 (2021).
- 31. Pan, C. et al. Shrinkage-mediated imaging of entire organs and organisms using uDISCO. *Nat. Methods* **13**, 859–867 (2016).
- 32. Jing, D. et al. Tissue clearing of both hard and soft tissue organs with the PEGASOS method. *Cell Res.* **28**, 803–818 (2018).
- Kosmidis, S., Negrean, A., Dranovsky, A., Losonczy, A. & Kandel, E. R. A fast, aqueous, reversible three-day tissue clearing method for adult and embryonic mouse brain and whole body. *Cell Rep. Meth.* 1, 100090 (2021).
- Susaki, E. A. et al. Versatile whole-organ/body staining and imaging based on electrolyte-gel properties of biological tissues. *Nat. Commun.* 11, 1982 (2020).
- Goc, J., Fridman, W. H., Sautès-Fridman, C. & Dieu-Nosjean, M. C. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2, e26836 (2013).
- Fletcher, A. L., Acton, S. E. & Knoblich, K. Lymph node fibroblastic reticular cells in health and disease. *Nat. Rev. Immunol.* 15, 350–361 (2015).

- Takemura, S. et al. Lymphoid neogenesis in rheumatoid synovitis1.
   J. Immunol. 167, 1072–1080 (2001).
- Srikakulapu, P. & McNamara, C. A. B cells and atherosclerosis. Am. J. Physiol. Heart. Circ. Physiol. **312**, H1060–H1067 (2017).
- Magliozzi, R. et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. *Ann. Neurol.* 68, 477–493 (2010).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.

© The Author(s) 2023

#### Article

### Methods

#### Animals involved in the study

We used the following mix-gender animals for the wildDISCO study: 4-week-old, 6-week-old and 3-month-old wildtype mix-gender mice (C57BL/6J, CD-1 IGS and Balb/c) purchased from Charles River Laboratories. Animals were housed on a 12/12 h light/dark cycle and had random access to food and water. Temperature was maintained at 18-23 °C and humidity was at 40-60%. The 4-week-old and 3-month-old C57BL/6J germ-free mix-gender mice were purchased from the Technical University of Munich (Institute of Nutrition and Health, Core Facility Gnotobiology), and were housed in a germ-free isolator house. The absence of bacteria was confirmed in the germ-free mice by microbial cultures, and mice were then used for further experiments. Each antibody was repeated successfully on at least five mice and also by at least three different people. Animal experiments were performed according to the institutional guidelines of the Ludwig Maximilian University of Munich and the Helmholtz Munich Center German Mouse Clinic after approval of the Ethical Review Board of the Government of Upper Bavaria (Regierung von Oberbayern, Munich, Germany).

#### Cyclodextrin buffer screening for cholesterol extraction

Cholesterol extraction was measured using the cholesterol/ cholesterol ester-GloTM assay (Promega). Here, 25 mg of paraformaldehyde (PFA) fixed mouse liver was incubated in 3 ml of 1% w/v different cyclodextrin-containing antibody buffers: 2-hydroxypropyl
β-cyclodextrin (PanReac AppliChem, A0367,0100), methyl-β-cyclodextrin (Sigma-Aldrich, 332615-25G), (2-hydroxyethyl)-β-cyclodextrin (Sigma-Aldrich, 389137-10G), triacetyl-β-cyclodextrin (Sigma-Aldrich, 332623-10G), succinyl-β-cyclodextrin (Sigma-Aldrich, 85990-500MG) and heptakis (2,6-di-O-methyl)-β-cyclodextrin (Sigma-Aldrich, 39915-1G). The assays were measured at different time points (2, 3, 5 and 7 d). Then, a 5 µl aliquot of the supernatant was diluted tenfold in cholesterol lysis solution and incubated for 30 min at 37 °C. Cholesterol detection reagent was then added to the samples and incubated for 60 min at room temperature. The value was measured using a Centro LB 96-plate reading luminometer (Berthold).

#### Cyclodextrin buffers' impact on antibody stabilization

The homogeneity of antibodies, in other words of antibody aggregations, in different cyclodextrin-containing buffers was measured by DLS. TH primary antibody was selected to evaluate antibody stabilization and homogeneity. TH antibody (Millipore, AB152) (molecular weight 150 kDa, concentration 10 g l<sup>-1</sup>) was dissolved in HEPES buffer (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) with and without CD5 (Sigma-Aldrich, 39915-1G) (1% w/v) at room temperature. After 7 days of incubation, the buffer solutions were diluted and afterward measured in a folded capillary cell (DTS 1070) using a Zetasizer Nano ZS. Samples were measured three times with six sub-runs each. The temperature was set to 25 °C.

#### Permeabilization of brain with cyclodextrin buffers

Mouse half brains were incubated with various cyclodextrin buffers at 1% (w/v), 45 ml for 3 days at 37 °C. After washing twice with PBS, the samples had 45 ml of 0.03% methylene blue added to them and were incubated overnight at 37 °C.

To determine the efficiency of methylene blue staining after incubation with different cyclodextrin buffers, samples were cut in half along the middle line to evaluate the efficacy of the inner tissue staining. The methylene blue-stained mouse brains were cryosectioned into 10 µm slices for higher resolution images using Zeiss Axio Imager. M2 microscopy. The images of the samples were analyzed by ImageJ for profile plot along and the pixels were quantified under threshold gray value.

#### Breast cancer metastasis model

Some 4T1 breast cancer cells, encoded with EGFP and enhanced firefly luciferase, were filtered through a 100  $\mu$ m membrane and resuspended in RPMI 1640 medium (GIBCO, 11875093). For the subcutaneous injection model, 1 × 10<sup>6</sup> cancer cells (50  $\mu$ l) were injected into the fourth left and right mammary fat pads of 6-week-old female Balb/c mice. After 14 days, the metastases of mice were measured by bioluminescence using IVIS Lumina II Imaging System (Caliper Life Sciences). Briefly, the mice were anesthetized with ketamine, fixed in the imaging chamber and imaged 15 min after injection of luciferin (150 mg kg<sup>-1</sup>, intraperitoneal injection). The bioluminescence signal was quantified using Living Image Software v.4.2 (Caliper Life Sciences). After confirmation of metastasis occurrence by IVIS imaging, the mice were euthanized and stained with two antibodies CD3 and CD23 to confirm TLS.

#### Perfusion and whole mouse body fixation

Mice were deeply anesthetized with MMF (0.05 mg kg<sup>-1</sup> fentanyl, 0.5 mg kg<sup>-1</sup> medetomidine and 5 mg kg<sup>-1</sup> midazolam with intraperitoneal injection) and perfused intracardially with heparinized 0.01 MPBS (10–25 U ml<sup>-1</sup> final heparin concentration, Ratiopharm, N68542.03; perfusion volume 12 ml min<sup>-1</sup> with an ISMATEC peristaltic pump system). After washing the blood out of the mice for 5–10 min, 4% PFA in 0.01 M PBS (Morphisto, 11762.01000) was perfused 10–20 min. The mouse bodies were skinned and transferred to 0.01 M PBS after postfixation in 4% PFA for 6 h at 4 °C.

#### Whole-body staining with wildDISCO protocol

The wildDISCO whole-body immunostaining protocol is mainly based on a setup for pumping the pretreatment solutions and immunostaining buffers through the mouse heart and vasculature to perfuse the whole body. The pumping setup has been previously described<sup>6,13</sup>. In brief, after postfixation of PFA and 0.1 MPBS washing twice for 30 min, the mouse body was placed in a 300 ml glass chamber and the perfusion needle was inserted into the mouse heart through the same hole as in PFA perfusion. Then, the perfusion needle was connected to an ISMATEC peristaltic pump (REGLO Digital MS-4/8 ISM 834; reference tube, SC0266), which maintained pressure at 160-230 mmHg (45-60 rpm) and was used to establish transcardiac circulation. The pump was equipped with two channels. One was used to pump the solution through the heart to circulate throughout the mouse, while the second channel collected and circulated the solution leaving the mouse body. In the first channel, a 1-ml syringe tip (Braun, 9166017V) was used to connect the perfusion needle (Leica, 39471024) and the reference tube (Ismatec Reglo, SC0266), which is from the pump and set for circulation of the solution through the heart into the vasculature. Since the second channel allowed the solutions to recirculate, the inflow tubing was immersed in the solution chamber of the glass chamber. After the pump and channels are set up, the needle tip was fixed with superglue (Pattex, PSK1C) to ensure continuing and stable perfusion. All the following perfusion steps were performed using the setup explained above. The mice were first perfused with 0.1 M PBS overnight at room temperature, followed by 2 days of perfusion with the decalcification solution containing 10 w/v% EDTA (Carl Roth, 1702922685) in 0.1 M PBS, and the pH was adjusted to 8-9 with sodium hydroxide (Sigma-Aldrich, 71687) to decalcify all bones at room temperature. Then, the mouse bodies were perfused three times with 0.1 M PBS and washed for 3 h each time. Next, each mouse was perfused for 1 day with permeabilization and blocking solution containing 10% goat serum and 2% Triton X-100 in 0.1 M PBS. Next, the mice bodies were perfused with primary antibodies (antibodies are listed in Supplementary Table 1; validated antibody list http://discotechnologies.org/wildDISCO/) and incubated for 7 days with 250 ml of immunostaining buffer containing 3% goat serum, 10% CHAPS, 2% Triton X-100, 10% dimethylsulfoxide (DMSO), 1% glycine, 1% CD5 in 0.1 M PBS. Each mouse body was then washed three times in 0.1 M PBS and each time took 12 h at room temperature.

Then, the mice bodies were perfused in the immunostaining buffer at room temperature with the Alexa fluorescent dye-conjugated secondary antibodies: Alexa Fluor 647 goat antirabit IgG antibody (Thermo Fisher Scientific, A-21245) or Alexa Fluor 647 goat antirat IgG antibody (Thermo Fisher Scientific, A-21247) (25  $\mu$ g in 250 ml, diluted 1:10,000) for 7 days. The mice bodies were washed three times with 0.1 M PBS, each time for 12 h. After the immunostaining steps were done, the mice were transferred to a fume hood and were cleared using the 3DISCO passive whole-body clearing protocol as previously reported<sup>9</sup>. Briefly, mice bodies were placed in a 300 ml glass chamber and immersed in 200 ml of the following gradient of tetrahydrofuran (Roth, CP82.1) in distilled water with gentle shaking (50% once, 70% once, 80% once, 100% twice, 12 h for each step), followed by 3 h in dichloromethane (Sigma, 270997) and finally in benzyl alcohol and benzyl benzoate (ratio of 1:2, Sigma, 24122 and W213802) until the bodies were optically transparent.

#### Comparison of different whole-body clearing methods

The detailed protocol of vDISCO was described previously<sup>5</sup>. However, all previously used nanoboosters were replaced with commercial IgG antibodies at a concentration of 25 µg per mouse. For the iDISCO antibody staining method, we followed the original iDISCO+ publication<sup>11</sup> and the latest protocol updates from https://idisco.info. Briefly, each step was adjusted to the whole-body level instead of the organ-level (for example, the duration of methanol dehydration was increased to 6 h). After pretreatment with methanol, the entire body was treated with a series of iDISCO+ solutions. For immunolabeling, the whole mouse was treated with the primary antibody (Synapsin-1, CST, no. 5297, 25 µg in 250 ml, diluted 1:10,000) in the first solution (0.2% Tween-20, 5% DMSO, 3% donkey serum, 1 mg l<sup>-1</sup> heparin in PBS) at 37 °C for 7 days and then incubated with a secondary antibody (Alexa Fluor 647 goat antirabbit IgG antibody, Thermo Fisher Scientific, A-21245, 25 µg in 250 ml, diluted 1:10,000) in the second solution (0.2% Tween-20, 5% DMSO, 3% donkey serum, 1 mg l<sup>-1</sup> in PBS) at 37 °C for 7 days. Finally, the whole mouse was cleared until it became optically transparent. For the uDISCO and PEGASOS whole mouse labeling, the immunostaining buffer and process were adopted from the iDISCO methods. Afterward, the clearing steps of uDISCO and PEGASOS were performed based on the original publications<sup>31,32</sup>.

#### Light-sheet microscopy imaging

Image stacks were acquired using a Blaze ultramicroscope (LaVision BioTec GmbH, v.7.3.2) with an axial resolution of 4 um and the following filter sets: excitation 470/40 nm. emission 535/50 nm: excitation 545/25 nm, emission 605/70 nm and excitation 640/40 nm, emission 690/50 nm. Whole mouse bodies were scanned individually with an UltraMicroscope Blaze light-sheet microscopy ×4 objective (Olympus XLFLUOR ×4 corrected/0.28 numerical aperture (working distance, 10 mm)). We covered the entire mouse in with  $9 \times 23$  tile scans with 20% overlap and imaged them separately from the ventral and dorsal surfaces to a depth of 10 mm, covering the entire body volume with a z step of 10  $\mu$ m. The width of the light sheet was reduced to 60% to achieve maximum illumination of the field of view, and the exposure time was set to 120 ms. The laser power was adjusted as a function of the intensity of the fluorescence signal to avoid saturation. The acquired raw images TIFF were processed with the Fiji stitching plugin (http:// www.discotechnologies.org/).

#### Reconstructions of full-body scans and quantification

Detailed step-by-step instructions for image data stitching and volume fusion were provided previously<sup>6</sup>. Briefly, image stacks were recorded using ImSpector software (LaVision BioTec GmbH) and saved in TIFF format for each channel separately. The scanned ventral and dorsal-mouse image data were first stitched using the Fiji stitching plugin and volumes fused using Vision4D (v.3.5x64, Arivis AG, v.3.4.0). To increase the precision of volume fusion, alignment was performed by manually selecting three to four anatomical landmarks from the overlapping regions. Representative images were created using Imaris (Bitplane AG, v.9.6.0) and Vision4D for 3D volumetric reconstruction, maximum intensity projection and depth color rendering. To isolate a specific tissue region, the Imaris surface tool was used manually and the mask channel option for pseudocolor was selected. After manual segmentation, the region was visualized in 2D slices using the Ortho Slicer tool. VR pictures and Videos were generated using the Syglass software (IstoVisio, Inc., v.1.7.2).

For quantification of the enteric plexus in the duodenum between germ-free mice and wildtype mice, five  $200 \times 200 \times 200 \ \mu m^3$  cubic volumes along the portal triads were randomly selected from the reconstructed 3D images in Imaris. The length of the PGP 9.5-positive enteric plexus in each cubic volume was traced using Imaris Filament Tracer.

#### **Colocalization analysis**

Colocalization analysis was carried out using BitPlane Imaris. To quickly analyze the colocalization ratio, the whole-body data were cropped to specific organ and tissue data. Both filament tracer and surface rendering in Imaris were applied to calculate the colocalization ratios.

#### Spatial quantification between TLS and metastases

Given a 3D annotation of TLS and metastases, we used the cc3d library to implement connected component analysis to label every TLS and metastases, and obtain the positions of their centroids. Using the centroid information, we computed the distances to the nearest neighboring metastases, the nearest neighboring TLS and between TLS and metastases. In addition, we calculated the volume and size of every TLS and metastases using the labeled connected component results.

#### VR headset procedure

Supplementary Videos 24–31 require a VR headset. To visualize them, you need a VR video player on your VR device or computer. Videos played in VR need to have '\_360' at the end of their file name and be set to a '360°/3D' view in the VR player for an immersive experience.

#### Whole mouse atlas website construction

We constructed the entire mouse atlas website by stitching together imaging data obtained from light-sheet microscopy using ImageJ/Fiji (v.1.53) and the plugin 'stich sequence of grids of images'. Afterward, we compressed the entire image dataset using ImageMagick LZW compression software to reduce data size from several terabytes to a few hundred gigabytes. We used the ome-zarr-py tool to convert the compressed TIFF image format to the OME-Zarr image format. The resulting OME-Zarr images are now accessible via webKnossos<sup>40</sup>.

#### Quantification

Data are presented as mean  $\pm$  s.d. Statistical analysis was performed using Prism GraphPad software v.6 with 95% confidence interval. *P* values were calculated using two-tailed unpaired *t*-tests to compare data between two groups. *P* < 0.05 were considered statistically significant.

#### **Reporting summary**

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

#### **Data availability**

All data that support the findings of this study are available from the corresponding author upon reasonable request. An atlas of high-resolution images of whole mouse nervous systems is available at http://discotechnologies.org/wildDISCO/atlas/index.php. Source data are provided with this paper.

#### Reference

 Boergens, K. M. et al. webKnossos: efficient online 3D data annotation for connectomics. Nat. Methods 14, 691–694 (2017).

#### Acknowledgements

Illustration (Supplementary Fig. 2) was created with BioRender.com. H.M. and Y.C. thank the China Scholarship Council for the financial support (grant nos. 201806780034 and 202206020082). We thank L. Peng (Department of Pharmacy, LMU Munich) and Y. Lin (Department of Pharmacy, LMU Munich) for DLS measurements. This work was supported by the Vascular Dementia Research Foundation, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy, grant no. ID 390857198) and DFG (grant nos. SFB 1052, project A9; TR 296 project 03) as well as the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) within the NATON collaboration (grant no. 01KX2121). This work was also supported by the European Research Council Consolidator grant (no. GA 865323, A.E.) and Nomis Heart Atlas Project Grant (Nomis Foundation).

### **Author contributions**

A.E. conceived and led all aspects of the project. H.M. and J.L. developed the method and conducted most of the experiments. R.A.-M., F.K., Y.C., J.M., I.H., M.P., J.C.P. and M.T. analyzed data. L.H. generated VR videos. A.E. and F.H. supervised the project. J.L. and H.M. wrote the first draft of the paper. M.E. edited the paper. A.E. wrote the final paper. All authors reviewed and approved the final manuscript.

#### Funding

Open access funding provided by Helmholtz Zentrum München -Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH).

#### **Competing interests**

A.E., H.M. and J.L. are also employees of Deep Piction. A.E., H.M. and J.L. filed an intellectual property on technologies described here. The remaining authors declare no competing interests.

## **Additional information**

**Extended data** is available for this paper at https://doi.org/10.1038/s41587-023-01846-0.

**Supplementary information** The online version contains supplementary material available at https://doi.org/10.1038/s41587-023-01846-0.

**Correspondence and requests for materials** should be addressed to Ali Ertürk.

**Peer review information** *Nature Biotechnology* thanks Alain Chedotal and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at www.nature.com/reprints.



**Extended Data Fig. 1** | **PGP9.5 peripheral nerve system.** wildDISCO immunostaining of PGP9.5 throughout the mouse body (**a**) Maximum projection of the peripheral nervous system of a 4-week-old mouse stained with PGP

9.5 antibody using light sheet microscopy.  $(\mathbf{b}-\mathbf{e})$  Examples of positive PGP 9.5 staining in different organs (heart, spleen, liver, and intestine) with more magnified areas. n = 3.



**Extended Data Fig. 2** | **TH staining in brain.** (**a**) Representative image of a 4-week-old mouse stained with TH antibody using lightsheet microscopy. (**b**-**c**) Examples of positive TH staining in the expected brain regions (**b**) with higher

magnification areas showing TH-positive neuron  $axon(\mathbf{c})$ , the red long arrow indicates neuron cell bodies, while the green short arrow indicates neuron filaments. n = 3.



**Extended Data Fig. 3** | **LYVE1 lymphatic vessel system.** wildDISCO enables immunostaining of LYVE1 throughout the mouse body. Examples of optical sections of whole mouse staining with LYVE1 antibody in different organs, liver

(a), hindlimbs (b), adipose tissue (c), kidney (d), trachea (e), stomach (f), and intestine (g) with higher magnified regions. (a-g), n = 3. (h-i) 3D reconstruction view of the intestinal lymphatic network using Syglass software.



**Extended Data Fig. 4** | **alpha-SMA artery system.** (**a**) depth color map of the entire mouse body stained with alpha-SMA. Examples of optical sections of whole mouse staining with alpha-SMA antibody in different organs, liver (**b**), lung (**c**), kidney (**d**), and gut (**e**). n = 3.



**Extended Data Fig. 5** | **The integrity of alpha SMA artery system.** (a) Examples of optical sections of whole mice stained with alpha-SMA to show the integrity of the vasculature in various organs: head (a), heart (b), higher magnification of heart regions (c), multiple connected internal organs (d) with higher magnification regions: spinal cord (e), liver (f), and kidney (g). n = 3.



**Extended Data Fig. 6** | **Interactions between nerves and immune cells in the gut.** (a) 3D reconstruction view of a Peyer's patch in the gut stained with CD45 (green) and innervated by TH + sympathetic nerve (magenta) visualized with Syglass software. (b) Sympathetic nerve marker TH (green) and immune cell marker CD45 (magenta) on the intestinal wall visualized with Imaris software.



**Extended Data Fig. 7** | **Nerve-lymphatic vessel interactions in the gut.** (a) PGP9.5 nerve fibers (magenta) interacted with Prox1 lymphatic vessel (green). (b) TH sympathetic nerve (green) and LYVE1 lymphatic vessel (magenta). n = 3.



**Extended Data Fig. 8** | **Influence of the microbiota on sympathetic nerves of mice.** (**a**-**b**) The enteric nerve lattice network of WT mice and germ-free mice by immunostaining with antibodies against TH. Higher magnification views of the regions marked by the white and yellow boxes, respectively. n = 3.



**Extended Data Fig. 9** | **CD23 whole mouse body staining and confirmation of CD3 cluster in TLS structure.** (a) wildDISCO immunostaining of mature TLS marker CD23 in the whole mouse body of 4T1 cancer metastasis. (b) Representative 2D optical image of lung metastasis with immune cell marker CD45 in red and T cell marker CD3 in magenta to confirm TLS structure. n = 3.



**Extended Data Fig. 10** | **Proliferation Ki67**+ **cells in whole mouse body.** (a) wildDISCO immunostaining of cell proliferation marker Ki67 (cyan) and PI (magenta) in the whole mouse. (b) Representative 2D optical image of Ki67-positive proliferation cells (cyan) as rare cells compared to nuclear staining (propidium iodide, PI) in the bone marrow (b), vertebrate (c), gut

(d) and hippocampus (e). (f-g) Single proliferation cells identified in brain (f) and vertebrate (g) by whole-body light-sheet microscopy scans. Higher magnification images show colocalization of proliferation cells with a single nucleus. n = 3.

# nature portfolio

Corresponding author(s): Dr. Ali Erturk

Last updated by author(s): May 13, 2023

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

## Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	firmed
	$\boxtimes$	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	$\boxtimes$	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	$\boxtimes$	A description of all covariates tested
	$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	$\boxtimes$	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
		For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
$\boxtimes$		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\boxtimes$		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
$\boxtimes$		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

# Software and code

Policy information about availability of computer code						
Data collection	Data collection was performed using: ImSpector (Version 7.3.2, MiltenyiBioTec GmbH), Vision4D (Version 3.4.0, Arivis AG), Imaris (Version 9.6.0 Bitplane AG), syGlass(version 1.7.2), Living Image Software (Version 4.2 Caliper Life Sciences), ImageMagick LZW compression software (Version 7.0.5 ImageMagick Studio LLC)					
Data analysis	Data analysis was performed using: Fiji (version 1.53) , GraphpadPrism (version 6).					

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

#### Data availability

All data that support the findings of this study are available from the corresponding author upon reasonable request. Source data are provided with this paper. An atlas of high-resolution images of whole mouse nervous, lymphatic, and vascular systems is available at http://discotechnologies.org/wildDISCO/atlas/index.php Code availability

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

∑ Life sciences

Behavioural & social sciences

Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	ROIs from different parts of the tissue section were used for quantification of volume. Number of ROIs were noted in the figure legends.	
Data exclusions	No collected data were excluded.	
Replication	At least three replicates were performed with independent measurement and analysis.	
Randomization	Randomization was not necessary for this study.	
Blinding	Blinding was not pertinent to this study as experimental conditions were mostly evident from the image data.	

# Reporting for specific materials, systems and methods

Methods

n/a

 $\boxtimes$ 

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

MRI-based neuroimaging

Involved in the study

Flow cytometry

ChIP-seq

#### Materials & experimental systems

n/a	Involved in the study
	Antibodies
	Eukaryotic cell lines
$\boxtimes$	Palaeontology and archaeology
	Animals and other organisms
$\boxtimes$	Human research participants
$\boxtimes$	Clinical data
$\mathbf{X}$	Dual use research of concern

## Antibodies

Antibodies used	Anti-Tyrosine hydroxylase (TH) (Millipore, Cat# AB152) Anti-Tyrosine hydroxylase (TH) (Abcam, Cat# ab6211) Anti-Tyrosine hydroxylase (TH) (Cell Signaling Technology, Cat# 2792) Anti-PGP 9.5 (Proteintech, Cat# 14730-1-AP) Anti-S100 beta (Abcam, Cat# ab52642) Anti-Neurofilament NF-M (Covance, Cat# PRB-575C) Anti-Podoplanin (Life Technologies, Cat#MA529742) Anti-Peripherin (Merck Millipore, Cat#AB1530) Anti-Synapsin 1 (Cell Signaling, Cat#52975) Anti-Synapsin 2 (Cell Signaling, Cat#858525) Alexa Fluor647 anti-Tubulin β3 (BioLegend, Cat#801210) Alexa Fluor647 anti-Tubulin β3 (Abcam, Cat#ab190575) Anti-Tubulin (GeneTex Cat# GTX00877) Anti-β Tubulin (Abcam Cat# ab179513) Anti-Podocalyxin (R and D Systems, Cat# MAB1556) Anti-CD3 (Abcam, Cat# ab5690) Anti-CD23 (eBioscience, Cat# 14-0232-81) Anti-CD23 (Abcam, Cat# ab302526) Anti-Ki67 (Abcam, Cat# ab15580) Anti-Oct4 (Abcam, Cat# ab19857) Anti-Nestin (Santa Cruz, Cat# sc-101541) Anti-Myelin Basic Protein MBP (Sigma-Aldrich, Cat# MAB386) Anti-Sox2 (Cell Signaling, Cat#2748) Anti-PAX7 (Thermo Fisher Scientific, Cat# PA1-117) Anti-LGR5 (Abcam, Cat#ab19107) Anti-CGRP (Abcam, Cat#ab5475) Anti-Prox1 (Abcam, Cat# ab10851) Anti-Prox1 (Millipore, Cat# AB5475) Anti-Pox1 (Abcam, Cat# ab10851) Anti-LYVE1 (Thermo Fisher Scientific, Cat# 14-0443-82) Anti-GAP43 (Novus Biologicals, Cat# NB300-143) Anti-CD8 (Abcam, Cat# ab125212) Anti-PR peripheral benzodiazepine receptor (Abcam, Cat# ab109497) Anti-CD4 (eBioscience, Cat# A14-0041-82) Anti-CD8 (Thermo Fisher Scientific, Cat# A14-045-82) Anti-GAP43 (Novus Biologicals, Cat# NB300-143) Anti-CD8 (Abcam, Cat# ab125212) Anti-PR peripheral benzodiazepine receptor (Abcam, Cat# ab109497) Anti-CD4 (eBioscience, Cat# A14-0041-82) Anti-CD8 (Thermo Fisher Scientific, Cat# A5114996) Alexa Fluor 647 goat anti-rabbit IgG antibody (Thermo Fisher Scientific, Cat# A32733) Alexa Fluor 568 goat anti-rabbit IgG antibody (Thermo Fisher Scientific, Cat# A-21247) Alexa Fluor 568 goat anti-rabbit IgG antibody (Thermo Fisher Scientific, Cat# A-11036) Alexa Fluor 5
Validation	Anti-Tyrosine hydroxylase (TH) (RRID:AB_390204) Anti-Tyrosine hydroxylase (TH) (RRID:AB_2240393) Anti-Tyrosine hydroxylase (TH)

Anti-Tyrosine hydroxylase (TH) (RRID:AB\_390204) Anti-Tyrosine hydroxylase (TH) (RRID:AB\_2240393) Anti-Tyrosine hydroxylase (TH) (RRID:AB\_2303165) Anti-PGP 9.5 (RRID:AB\_2210497) Anti-S100 beta (RRID:AB\_882426) Anti-Neurofilament NF-M (RRID:AB\_291700) Anti-Podoplanin (RRID:AB\_2785565) Anti-Peripherin (RRID:AB\_90725) Anti-Synapsin 1 (RRID:AB\_2616578) Anti-Synapsin 2

(RRID:AB\_2800065) Alexa Fluor647 anti-Tubulin β3 (RRID:AB\_2686931) Anti-Podocalyxin (RRID:AB\_2166010) Anti-CD3 (RRID:AB\_443425) Anti-CD3 (RRID:AB\_443425) Anti-CD3 (RRID:AB\_443425) Anti-CD3 (RRID:AB\_443425) Anti-CD3 (RRID:AB\_445175) Anti-Nestin (RRID:AB\_1126570) Anti-Myelin Basic Protein MBP (RRID:AB\_94975) Anti-Sox2 (RRID:AB\_823640) Anti-PAX7 (RRID:AB\_2539886) Anti-CGRP (RRID:AB\_725807) Anti-Alpha smooth muscle actin SMA (RRID:AB\_2223021) Anti-Collagen IV (RRID:AB\_305584) Anti-Prox1 (RRID:AB\_177485) Anti-Prox1 (RRID:AB\_10712211) Anti-LYVE1 (RRID:AB\_1633414) Anti-Iba1 (RRID:AB\_305584) Anti-CD45 (RRID:AB\_467251) Anti-CD45 (RRID:AB\_442810) Anti-GAP43 (RRID:AB\_10001196) Anti-CD68 (RRID:AB\_10975465) Anti-PBR peripheral benzodiazepine receptor (RRID:AB\_10862345) Anti-CD4 (RRID:AB\_467063) Anti-CD8 (RRID:AB\_2899632) Alexa Fluor 647 Anti-GFP (RRID:AB\_162553) Anti-CD19 (RRID:AB\_657669) Alexa Fluor Fluor 647 goat anti-rabbit IgG antibody (RRID:AB\_141778) Alexa Fluor 568 goat anti-rabbit IgG antibody (RRID:AB\_1053566) Alexa Fluor 568 goat anti-rat IgG antibody (RRID:AB\_2534121)

All of the antibodies used in this study were obtained from commercial sources, as described, and were validated by the respective manufacturer. Detailed information about the validation and references for each antibody can be accessed through the vendor websites, which can be reached via the catalog numbers listed above. Based on the vendor websites or several references, most of the antibodies used in this study have been tested and found to be suitable for IHC/IF applications. In our experiments, the imaging patterns of the antibodies were found to be consistent with the reference IF patterns and matched the expected distribution based on the existing literature, for both direct and indirect immunolabeling. These findings provide additional support for the validity and accuracy of the antibody labeling in our study.

## Eukaryotic cell lines

Policy information about <u>cell lines</u>				
Cell line source(s)	4T1 Cell line was purchased from ATCC (ATCC CRL-2539™).			
Authentication	ATCC authenticated the cells.			
Mycoplasma contamination	Cell lines were not tested for mycoplasma contamination.			
Commonly misidentified lines (See <u>ICLAC</u> register)	No commonly misidentified cell lines were used.			

# Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

4-week-old and 3-month-old mixed-gender wildtype mice (C57BL/6J, CD1 and Balb/c) were purchased from Charles River Laboratories, C57BL/6J germ-free mice were purchased from the Technical University of Munich, Institute of Nutrition and Health, Core Facility Gnotobiology
This study does not involve wild animals.
This study does not involve field-collected samples.
Animal experiments were performed according to the institutional guidelines of the Ludwig Maximilian University of Munich and the Helmholtz Munich Center German Mouse Clinic after approval of the Ethical Review Board of the Government of Upper Bavaria (Regierung von Oberbayern, Munich, Germany).

Note that full information on the approval of the study protocol must also be provided in the manuscript.